Page 105 - Predicting survival in patients with spinal bone metastasesL

Table 1. Patient characteristics.
Gender Male
Female
Age (years, mean ± SD) Primary tumor
Lung Breast Kidney Colon Esophagus Prostate Other
Karnofsky performance status Normal (100-80%) Impaired (70-10%)
Missing
Frankel classification
No deficit (E)
Minor motor or sensory deficit (D) Major motor or sensory deficit (A,B,C)
Expected survival A - Good
B - Moderate
C - Poor
D – Very poor
Missing
Total radiotherapy dose
8 Gy 16 Gy ≥24 Gy
59 (54)
51 (46) 60.4 ± 13.8
25 (23) 18 (16) 17 (16) 14 (13) 9 (8)
8 (7) 19 (17)
59 (54) 46 (42) 5 (4)
67 (61) 40 (36) 3 (3)
6 (5) 28 (26) 57 (52) 14 (13) 5 (4)
36 (33) 26 (24) 48 (43)
SINS
Characteristic
N (%)
The overall median survival was 6.6 months (95%CI 5.5-7.7) with a median follow-up of 5.2 years. Seventy-nine patients (72%) died within 12 months after starting treatment. A total of 16 patients (15%) experienced an adverse event during follow-up. Among them, eight patients (50%) experienced a deterioration of spinal alignment for which they were surgically stabilized and eight patients (50%) experienced a pathologic fracture, or progression of their existing fracture. In figure 1 the cumulative incidence of the two competing events is illustrated. The cumulative incidences for the occurrence of an adverse event at 6 and 12 months were 11.8% (95%CI 5.1%-24.0%) and 14.5% (95%CI 6.9%-22.2%), respectively.
VII
103